Abstract
Insulin resistant individuals manifest multiple disturbances in free fatty acids metabolism and have excessive lipid accumulation in insulin-target tissues. A wide range of evidence suggests that defective muscle mitochondrial metabolism, and subsequent impaired ability to oxidize fatty acids, may be a causative factor in the accumulation of intramuscular lipid and the development of insulin resistance. Such mitochondrial dysfunction includes loss of mitochondria, defects in the mitochondrial OXPHOS system and decreased rate of ATP synthesis. Stimulation of mitochondrial biogenesis appears as a strategy for the clinical management of the metabolic syndrome, by enhancing mitochondrial activity and protecting the cell against the increased flux of reduced substrates to the electron transport chain and thus reducing metabolic inflammation.
Keywords: Metabolic diseases, SIRT1, AMPK, PGC-1α, mitochondria, biogenesis, oxidative phosphorylation, cellular metabolism, high-fat diets, obesity
Current Drug Targets
Title: Regulation of Mitochondrial Biogenesis in Metabolic Syndrome
Volume: 12 Issue: 6
Author(s): Anabela P. Rolo, Ana P. Gomes and Carlos M. Palmeira
Affiliation:
Keywords: Metabolic diseases, SIRT1, AMPK, PGC-1α, mitochondria, biogenesis, oxidative phosphorylation, cellular metabolism, high-fat diets, obesity
Abstract: Insulin resistant individuals manifest multiple disturbances in free fatty acids metabolism and have excessive lipid accumulation in insulin-target tissues. A wide range of evidence suggests that defective muscle mitochondrial metabolism, and subsequent impaired ability to oxidize fatty acids, may be a causative factor in the accumulation of intramuscular lipid and the development of insulin resistance. Such mitochondrial dysfunction includes loss of mitochondria, defects in the mitochondrial OXPHOS system and decreased rate of ATP synthesis. Stimulation of mitochondrial biogenesis appears as a strategy for the clinical management of the metabolic syndrome, by enhancing mitochondrial activity and protecting the cell against the increased flux of reduced substrates to the electron transport chain and thus reducing metabolic inflammation.
Export Options
About this article
Cite this article as:
P. Rolo Anabela, P. Gomes Ana and M. Palmeira Carlos, Regulation of Mitochondrial Biogenesis in Metabolic Syndrome, Current Drug Targets 2011; 12 (6) . https://dx.doi.org/10.2174/138945011795529056
DOI https://dx.doi.org/10.2174/138945011795529056 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Flow Cytometry Study of Leukocyte Function: Analytical Comparison of Methods and their Applicability to Clinical Research
Current Medicinal Chemistry Evaluation of Risk Factors Associated with Diabetic Foot Ulcers in Saudi Arabia
Current Diabetes Reviews Management of Hypertension-Journey from Single Drug Therapy to Multitargeted Ligand Therapy: A Clinical Overview
Current Clinical Pharmacology Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Current Vascular Pharmacology Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Maternal Nutrition and Predisposition to Later Kidney Disease
Current Drug Targets Ribosome Inactivating Proteins (RIPs) from Momordica charantia for Anti Viral Therapy
Current Molecular Medicine Polymorphism rs9939609 of Fat Mass and Obesity-associated Gene Correlation with Leptin Level of Obese Women Suffered from Type 2 Diabetes
Current Diabetes Reviews Recent Advances in Obesity Pharmacotherapy
Current Clinical Pharmacology Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Salusins in Hypertension and Related Cardiovascular Diseases
Current Drug Metabolism Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Analyzing the Amperometric Response of a Glucose Oxidase Sensor Applying Mathematical Models
Current Analytical Chemistry Clinical Effectiveness of a High Dose Versus the Standard Dose of Meropenem in Ventilator-associated Pneumonia Caused by Multidrugresistant Bacteria: A Randomized, Single-blind Clinical Trial
Infectious Disorders - Drug Targets Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus
Current Medicinal Chemistry Subject Index To Volume 12
Current Pharmaceutical Design Association Between Polycystic Ovary Syndrome and Metabolic Syndrome
Current Medicinal Chemistry Polyphenols and Stem Cells for Neuroregeneration in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Vascular Protective Effects of Diabetes Medications that Mimic or Increase Glucagon-Like Peptide-1 Activity
Recent Patents on Cardiovascular Drug Discovery From Chemical Graphs in Computer-Aided Drug Design to General Markov-Galvez Indices of Drug-Target, Proteome, Drug-Parasitic Disease, Technological, and Social-Legal Networks
Current Computer-Aided Drug Design